The U.S. Food and Drug Administration (FDA) has approved Cue Health's at-home COVID-19 test, making it the first coronavirus test to get marketing authorization using a traditional premarket review.
The test, which is a nasal swab test, can detect COVID-19 in as little as 15 minutes. It is 98% accurate in detecting symptomatic people who are up to four days after their infection, and 95% accurate in detecting asymptomatic people who are up to three days after their infection.
The test is available for purchase online and at select retailers. It costs $199 per kit, which includes two tests.
The approval of Cue Health's test is a significant development in the fight against COVID-19. It provides consumers with an easy and convenient way to test for the virus at home. This could help to reduce the spread of the virus by encouraging people to get tested more often.
Cue Health is a San Francisco-based company that was founded in 2019. The company's mission is to make healthcare more accessible and affordable.
Here are some creative titles for the news article:
- Cue Health's At-Home COVID Test Gets FDA Approval
- First At-Home COVID Test Gets FDA Approval
- Cue Health's COVID Test Now Available to Consumers
- At-Home COVID Testing Gets a Boost with FDA Approval
- New At-Home COVID Test Offers Convenient and Affordable Option for Consumers
These titles are creative because they use interesting language and imagery to capture the reader's attention. They also highlight the key aspects of the story, such as the FDA approval of Cue Health's at-home COVID test, the fact that it is the first at-home test to get FDA approval, and the convenience and affordability of the test.
People also ask
⚐ What are the top stocks to invest in right now?☵ What happens to stocks when they're delisted?